RANK–RANKL signalling in cancer
暂无分享,去创建一个
M. Heymann | D. Heymann | Dominique Heymann | Frédéric Lezot | Nathalie Renema | Benjamin Navet | Marie-Françoise Heymann | F. Lézot | N. Renema | Benjamin Navet
[1] W. Blizek,et al. To the Bone , 2017, Journal of Religion & Film.
[2] K. Pienta,et al. The marrow niche controls the cancer stem cell phenotype of disseminated prostate cancer , 2016, Oncotarget.
[3] Mingyao Liu,et al. LGR4 is a receptor for RANKL and negatively regulates osteoclast differentiation and bone resorption , 2016, Nature Medicine.
[4] Ruo-Pan Huang,et al. Cytokines in cancer drug resistance: Cues to new therapeutic strategies. , 2016, Biochimica et biophysica acta.
[5] Yao Liu,et al. CCL20 mediates RANK/RANKL-induced epithelial-mesenchymal transition in endometrial cancer cells , 2016, Oncotarget.
[6] Roger D Kamm,et al. Impact of the physical microenvironment on tumor progression and metastasis. , 2016, Current opinion in biotechnology.
[7] A. Viola,et al. T Cells and Cancer: How Metabolism Shapes Immunity , 2016, Front. Immunol..
[8] M. Hansen,et al. Regulation of Osteoblast Migration Involving Receptor Activator of Nuclear Factor‐kappa B (RANK) Signaling , 2015, Journal of cellular physiology.
[9] Ming-qing Li,et al. RANKL/RANK interaction promotes the growth of cervical cancer cells by strengthening the dialogue between cervical cancer cells and regulation of IL-8 secretion. , 2015, Oncology reports.
[10] S. Aiba,et al. The Possible Interaction between Receptor Activator of Nuclear Factor Kappa-B Ligand Expressed by Extramammary Paget Cells and its Ligand on Dermal Macrophages. , 2015, The Journal of investigative dermatology.
[11] L. Bonewald,et al. Osteocytes, not Osteoblasts or Lining Cells, are the Main Source of the RANKL Required for Osteoclast Formation in Remodeling Bone , 2015, PloS one.
[12] K. Trieb,et al. Receptor activator of nuclear factor κB expression is a prognostic factor in human osteosarcoma. , 2015, Oncology letters.
[13] S. Aiba,et al. Receptor Activator of Nuclear Factor Kappa-B Ligand (RANKL) Promotes the Production of CCL17 from RANK|[plus]| M2 Macrophages , 2015 .
[14] Z. Werb,et al. The cancer stem cell niche: how essential is the niche in regulating stemness of tumor cells? , 2015, Cell stem cell.
[15] C. Sotiriou,et al. RANK-ligand (RANKL) expression in young breast cancer patients and during pregnancy , 2015, Breast Cancer Research.
[16] Yudong Wang,et al. MPA influences tumor cell proliferation, migration, and invasion induced by RANKL through PRB involving the MAPK pathway in endometrial cancer. , 2015, Oncology reports.
[17] Hao Zhang,et al. GPCR48/LGR4 promotes tumorigenesis of prostate cancer via PI3K/Akt signaling pathway , 2015, Medical Oncology.
[18] B. Fuchs,et al. RANK Ligand Blockade with Denosumab in Combination with Sorafenib in Chemorefractory Osteosarcoma: A Possible Step Forward? , 2014, Oncology.
[19] H. Park,et al. Expression of receptor activator of nuclear factor kappa‐B as a poor prognostic marker in breast cancer , 2014, Journal of surgical oncology.
[20] Zhiping Wang,et al. Potential role of the OPG/RANK/RANKL axis in prostate cancer invasion and bone metastasis. , 2014, Oncology reports.
[21] P. Ordóñez-Morán,et al. Complex metastatic niches: already a target for therapy? , 2014, Current opinion in cell biology.
[22] I. Holen,et al. Prostate Cancer Cells Preferentially Home to Osteoblast‐rich Areas in the Early Stages of Bone Metastasis: Evidence From In Vivo Models , 2014, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[23] Yongwon Choi,et al. Biology of the RANKL–RANK–OPG System in Immunity, Bone, and Beyond , 2014, Front. Immunol..
[24] Q. Gao,et al. RANKL Promotes Migration and Invasion of Hepatocellular Carcinoma Cells via NF-κB-Mediated Epithelial-Mesenchymal Transition , 2014, PloS one.
[25] Z. Bago-Horvath,et al. Impact of RANK signalling on survival and chemotherapy response in osteosarcoma , 2014, Pathology.
[26] H. Gu,et al. RANK rs1805034 T>C Polymorphism Is Associated with Susceptibility of Esophageal Cancer in a Chinese Population , 2014, PloS one.
[27] Seema A. Khan,et al. RANKL expression in normal and malignant breast tissue responds to progesterone and is up-regulated during the luteal phase , 2014, Breast Cancer Research and Treatment.
[28] M. Heymann,et al. Novel RANK Antagonists for the Treatment of Bone‐Resorptive Disease: Theoretical Predictions and Experimental Validation , 2014, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[29] M. De la Fuente,et al. Chronic Inflammation and Cytokines in the Tumor Microenvironment , 2014, Journal of immunology research.
[30] Mark S. Anderson,et al. Brief Definitive Report , 2022 .
[31] C. Denkert,et al. RANK expression as a prognostic and predictive marker in breast cancer , 2014, Breast Cancer Research and Treatment.
[32] W. Dougall,et al. RANKL Inhibition Blocks Osteolytic Lesions and Reduces Skeletal Tumor Burden in Models of Non–Small-Cell Lung Cancer Bone Metastases , 2014, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[33] Yibin Kang,et al. Targeting tumor-stromal interactions in bone metastasis. , 2014, Pharmacology & therapeutics.
[34] Zuoqin Yan,et al. Stat3 Upregulates Leucine-Rich Repeat-Containing G Protein-Coupled Receptor 4 Expression in Osteosarcoma Cells , 2013, BioMed research international.
[35] Dali Li,et al. Lgr4 is a key regulator of prostate development and prostate stem cell differentiation , 2013, Stem cells.
[36] Klaus Pantel,et al. Tumor metastasis: moving new biological insights into the clinic , 2013, Nature Medicine.
[37] H. Yasuda. RANKL, a necessary chance for clinical application to osteoporosis and cancer-related bone diseases. , 2013, World journal of orthopedics.
[38] M. Heymann,et al. Osteoprotegerin: multiple partners for multiple functions. , 2013, Cytokine & growth factor reviews.
[39] T. Hagemann,et al. Tumour-associated macrophages and cancer. , 2013, Current opinion in pharmacology.
[40] David M. Thomas,et al. Safety and efficacy of denosumab for adults and skeletally mature adolescents with giant cell tumour of bone: interim analysis of an open-label, parallel-group, phase 2 study. , 2013, The Lancet. Oncology.
[41] R. Azevedo,et al. T Cells Induce Pre-Metastatic Osteolytic Disease and Help Bone Metastases Establishment in a Mouse Model of Metastatic Breast Cancer , 2013, PloS one.
[42] T. Akiyama,et al. Regulations of Gene Expression in Medullary Thymic Epithelial Cells Required for Preventing the Onset of Autoimmune Diseases , 2013, Front. Immunol..
[43] F. Tirode,et al. Osteoprotegerin inhibits bone resorption and prevents tumor development in a xenogenic model of Ewing's sarcoma by inhibiting RANKL , 2013, Journal of bone oncology.
[44] Daniel F. Gudbjartsson,et al. Nonsense mutation in the LGR4 gene is associated with several human diseases and other traits , 2013, Nature.
[45] W. Guo,et al. Differential Expression of the RANKL/RANK/OPG System Is Associated with Bone Metastasis in Human Non-Small Cell Lung Cancer , 2013, PloS one.
[46] H. Kalofonos,et al. Identification of novel human receptor activator of nuclear factor-kB isoforms generated through alternative splicing: implications in breast cancer cell survival and migration , 2012, Breast Cancer Research.
[47] C. Mueller,et al. Emerging Functions of RANKL in Lymphoid Tissues , 2012, Front. Immun..
[48] David M. Thomas,et al. Denosumab Induces Tumor Reduction and Bone Formation in Patients with Giant-Cell Tumor of Bone , 2012, Clinical Cancer Research.
[49] F. Climent,et al. RANK induces epithelial-mesenchymal transition and stemness in human mammary epithelial cells and promotes tumorigenesis and metastasis. , 2012, Cancer research.
[50] R. Khokha,et al. Homotypic RANK signaling differentially regulates proliferation, motility and cell survival in osteosarcoma and mammary epithelial cells , 2012, Journal of Cell Science.
[51] J. Massagué,et al. VCAM-1 promotes osteolytic expansion of indolent bone micrometastasis of breast cancer by engaging α4β1-positive osteoclast progenitors. , 2011, Cancer cell.
[52] Ye Zhang,et al. Receptor activator for nuclear factor κ B expression predicts poor prognosis in breast cancer patients with bone metastasis but not in patients with visceral metastasis , 2011, Journal of Clinical Pathology.
[53] E. Jimi,et al. The inhibition of RANKL/RANK signaling by osteoprotegerin suppresses bone invasion by oral squamous cell carcinoma cells. , 2011, Carcinogenesis.
[54] Gary D. Bader,et al. A comprehensive manually curated reaction map of RANKL/RANK-signaling pathway , 2011, Database J. Biol. Databases Curation.
[55] Y. Ohba,et al. RANKL expression specifically observed in vivo promotes epithelial mesenchymal transition and tumor progression. , 2011, The American journal of pathology.
[56] M. Heymann,et al. The Bone Niche of Chondrosarcoma: A Sanctuary for Drug Resistance, Tumour Growth and also a Source of New Therapeutic Targets , 2011, Sarcoma.
[57] Dong Ho Kim,et al. RANKL expression is related to treatment outcome of patients with localized, high‐grade osteosarcoma , 2011, Pediatric blood & cancer.
[58] C. Porta,et al. Receptor Activator of NF-kB (RANK) Expression in Primary Tumors Associates with Bone Metastasis Occurrence in Breast Cancer Patients , 2011, PloS one.
[59] I. Bièche,et al. Osteoprotegerin, a new actor in vasculogenesis, stimulates endothelial colony‐forming cells properties , 2011, Journal of thrombosis and haemostasis : JTH.
[60] T. Luger,et al. RANK is expressed in metastatic melanoma and highly upregulated on melanoma-initiating cells. , 2011, The Journal of investigative dermatology.
[61] C. Porta,et al. Expression pattern of receptor activator of NFκB (RANK) in a series of primary solid tumors and related bone metastases , 2011, Journal of cellular physiology.
[62] F. Tsai,et al. RANKL increases migration of human lung cancer cells through intercellular adhesion molecule‐1 up‐regulation , 2011, Journal of cellular biochemistry.
[63] William C Hines,et al. Why don't we get more cancer? A proposed role of the microenvironment in restraining cancer progression , 2011, Nature Medicine.
[64] J. Cheng,et al. Tumour-infiltrating regulatory T cells stimulate mammary cancer metastasis through RANKL–RANK signalling , 2011, Nature.
[65] M. Karin,et al. Inflammatory cytokines in cancer: tumour necrosis factor and interleukin 6 take the stage , 2011, Annals of the rheumatic diseases.
[66] D. Branstetter,et al. RANK ligand mediates progestin-induced mammary epithelial proliferation and carcinogenesis , 2010, Nature.
[67] Chun-Hao Tsai,et al. Involvement of integrin up‐regulation in RANKL/RANK pathway of chondrosarcomas migration , 2010, Journal of cellular biochemistry.
[68] R. Domsic,et al. Skin thickness progression rate: a predictor of mortality and early internal organ involvement in diffuse scleroderma , 2010, Annals of the rheumatic diseases.
[69] Yuk-Kwan Chen,et al. Immunohistochemical expression of RANKL, RANK, and OPG in human oral squamous cell carcinoma. , 2009, Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology.
[70] T. Wang,et al. Chronic inflammation, the tumor microenvironment and carcinogenesis. , 2009, Cell cycle.
[71] D. Heymann,et al. Factor VIII-von Willebrand Factor Complex Inhibits Osteoclastogenesis and Controls Cell Survival* , 2009, The Journal of Biological Chemistry.
[72] Y. Okada,et al. Increased RANKL expression is related to tumour migration and metastasis of renal cell carcinomas , 2009, The Journal of pathology.
[73] M. Padrines,et al. Proteases and bone remodelling. , 2009, Cytokine & growth factor reviews.
[74] E. Miot-Noirault,et al. Glycosaminoglycans as potential regulators of osteoprotegerin therapeutic activity in osteosarcoma. , 2009, Cancer research.
[75] B. Pitard,et al. Therapeutic efficacy of soluble receptor activator of nuclear factor-kappa B-Fc delivered by nonviral gene transfer in a mouse model of osteolytic osteosarcoma , 2010 .
[76] H. Takayanagi,et al. The tumor necrosis factor family receptors RANK and CD40 cooperatively establish the thymic medullary microenvironment and self-tolerance. , 2008, Immunity.
[77] F. Marshall,et al. Receptor activator of NF-κB Ligand (RANKL) expression is associated with epithelial to mesenchymal transition in human prostate cancer cells , 2008, Cell Research.
[78] J. Canon,et al. RANK ligand inhibition plus docetaxel improves survival and reduces tumor burden in a murine model of prostate cancer bone metastasis , 2008, Molecular Cancer Therapeutics.
[79] M. Heymann,et al. OPG, RANK and RANK ligand expression in thyroid lesions , 2008, Regulatory Peptides.
[80] W. Dalton,et al. The Bone Marrow Microenvironment as a Tumor Sanctuary and Contributor to Drug Resistance , 2008, Clinical Cancer Research.
[81] M. Seibel,et al. Bone resorption increases tumour growth in a mouse model of osteosclerotic breast cancer metastasis , 2008, Clinical & Experimental Metastasis.
[82] H. Ishii,et al. [Cancer stem cell]. , 2007, Nihon rinsho. Japanese journal of clinical medicine.
[83] B. Pitard,et al. Therapeutic relevance of osteoprotegerin gene therapy in osteosarcoma: blockade of the vicious cycle between tumor cell proliferation and bone resorption. , 2007, Cancer research.
[84] D. Heymann,et al. RANKL, RANK, osteoprotegerin: key partners of osteoimmunology and vascular diseases , 2007, Cellular and Molecular Life Sciences.
[85] B. Le Goff,et al. DU145 human prostate cancer cells express functional receptor activator of NFkappaB: new insights in the prostate cancer bone metastasis process. , 2007, Bone.
[86] B. Le Goff,et al. Human osteosarcoma cells express functional receptor activator of nuclear factor‐kappa B , 2007, The Journal of pathology.
[87] H. Takayanagi. Osteoimmunology: shared mechanisms and crosstalk between the immune and bone systems , 2007, Nature Reviews Immunology.
[88] N. Mochizuki,et al. Receptor activator of nuclear factor (NF)-kappaB ligand (RANKL) increases vascular permeability: impaired permeability and angiogenesis in eNOS-deficient mice. , 2007, Blood.
[89] H. Dinh,et al. RANK Overexpression in Transgenic Mice with Mouse Mammary Tumor Virus Promoter-Controlled RANK Increases Proliferation and Impairs Alveolar Differentiation in the Mammary Epithelia and Disrupts Lumen Formation in Cultured Epithelial Acini , 2006, Molecular and Cellular Biology.
[90] Y. Kadono,et al. Negative Regulation of Osteoclastogenesis by Ectodomain Shedding of Receptor Activator of NF-κB Ligand* , 2006, Journal of Biological Chemistry.
[91] M. Padrines,et al. OPG/membranous--RANKL complex is internalized via the clathrin pathway before a lysosomal and a proteasomal degradation. , 2006, Bone.
[92] C. Dinarello,et al. The paradox of pro-inflammatory cytokines in cancer , 2006, Cancer and Metastasis Reviews.
[93] A. Evdokiou,et al. RANK Expression as a Cell Surface Marker of Human Osteoclast Precursors in Peripheral Blood, Bone Marrow, and Giant Cell Tumors of Bone , 2006, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[94] Frédéric Blanchard,et al. Characterization of osteoprotegerin binding to glycosaminoglycans by surface plasmon resonance: Role in the interactions with receptor activator of nuclear factor κB ligand (RANKL) and RANK , 2006 .
[95] A. Potti,et al. Expression of RANKL/RANK/OPG in primary and metastatic human prostate cancer as markers of disease stage and functional regulation , 2006, Cancer.
[96] S. M. Sims,et al. Regulation of cancer cell migration and bone metastasis by RANKL , 2006, Nature.
[97] S. Ricard-Blum,et al. Characterization of osteoprotegerin binding to glycosaminoglycans by surface plasmon resonance: role in the interactions with receptor activator of nuclear factor kappaB ligand (RANKL) and RANK. , 2006, Biochemical and biophysical research communications.
[98] J. Penninger,et al. Receptor Activator of NF-κB Ligand Regulates the Proliferation of Mammary Epithelial Cells via Id2 , 2006, Molecular and Cellular Biology.
[99] S. Cross,et al. Expression of osteoprotegerin (OPG), TNF related apoptosis inducing ligand (TRAIL), and receptor activator of nuclear factor κB ligand (RANKL) in human breast tumours , 2006, Journal of Clinical Pathology.
[100] A. Kudo,et al. Self‐Assembled RANK Induces Osteoclastogenesis Ligand‐Independently , 2005, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[101] Sakae Tanaka,et al. RANK‐mediated amplification of TRAF6 signaling leads to NFATc1 induction during osteoclastogenesis , 2005, The EMBO journal.
[102] S. Théoleyre,et al. The molecular triad OPG/RANK/RANKL: involvement in the orchestration of pathophysiological bone remodeling. , 2004, Cytokine & growth factor reviews.
[103] S. Morrison,et al. Diverse mechanisms regulate stem cell self-renewal. , 2004, Current opinion in cell biology.
[104] L. Papucci,et al. In vitro blockade of receptor activator of nuclear factor‐κB ligand prevents osteoclastogenesis induced by neuroblastoma cells , 2004, International journal of cancer.
[105] M. Padrines,et al. RANKL/RANK/OPG: new therapeutic targets in bone tumours and associated osteolysis. , 2004, Biochimica et biophysica acta.
[106] Colin R Dunstan,et al. A Single‐Dose Placebo‐Controlled Study of AMG 162, a Fully Human Monoclonal Antibody to RANKL, in Postmenopausal Women , 2004, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[107] Ju-Hyun Kim,et al. RANKL regulates endothelial cell survival through the phosphatidylinositol 3′‐kinase/Akt signal transduction pathway , 2003, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[108] Y. Kong,et al. Vascular Endothelial Growth Factor Up-regulates Expression of Receptor Activator of NF-κB (RANK) in Endothelial Cells , 2003, Journal of Biological Chemistry.
[109] R. Rezzonico,et al. The receptor activator of nuclear factor (NF)κB ligand (RANKL) is a new chemotactic factor for human monocytes , 2003 .
[110] C. Mongini,et al. RANKL expression in a case of follicular lymphoma , 2003, European Journal of Haematology.
[111] P. Croucher,et al. Recombinant osteoprotegerin decreases tumor burden and increases survival in a murine model of multiple myeloma. , 2003, Cancer research.
[112] T. Plesner,et al. Osteoprotegerin is bound, internalized, and degraded by multiple myeloma cells. , 2002, Blood.
[113] E. Milgrom,et al. RANK (receptor activator of nuclear factor‐κB) and RANKL expression in multiple myeloma , 2002, British journal of haematology.
[114] F. Hamdy,et al. Osteoprotegerin (OPG) is a survival factor for human prostate cancer cells. , 2002, Cancer research.
[115] Y. M. Lee,et al. TNF-related Activation-induced Cytokine (TRANCE) Induces Angiogenesis through the Activation of Src and Phospholipase C (PLC) in Human Endothelial Cells* , 2002, The Journal of Biological Chemistry.
[116] E. Milgrom,et al. RANK (receptor activator of nuclear factor kappa B) and RANK ligand are expressed in giant cell tumors of bone. , 2002, American journal of clinical pathology.
[117] M. Matsuoka,et al. Mechanism of hypercalcemia in adult T-cell leukemia: overexpression of receptor activator of nuclear factor kappaB ligand on adult T-cell leukemia cells. , 2002, Blood.
[118] B. Aggarwal,et al. Functional expression of receptor activator of nuclear factor kappaB in Hodgkin disease cell lines. , 2001, Blood.
[119] William Maloney,et al. Receptor Activator of NF-κB and Osteoprotegerin Expression by Human Microvascular Endothelial Cells, Regulation by Inflammatory Cytokines, and Role in Human Osteoclastogenesis* , 2001, The Journal of Biological Chemistry.
[120] K. Hirokawa,et al. Determination of Three Isoforms of the Receptor Activator of Nuclear Factor-κΒ Ligand and Their Differential Expression in Bone and Thymus. , 2001, Endocrinology.
[121] A. Nakanishi,et al. The Effect of a Single Dose of Osteoprotegerin in Postmenopausal Women , 2001, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[122] D. Lacey,et al. The Osteoclast Differentiation Factor Osteoprotegerin-Ligand Is Essential for Mammary Gland Development , 2000, Cell.
[123] D L Lacey,et al. RANK is the intrinsic hematopoietic cell surface receptor that controls osteoclastogenesis and regulation of bone mass and calcium metabolism. , 2000, Proceedings of the National Academy of Sciences of the United States of America.
[124] T. Miyata,et al. Commitment and Differentiation of Osteoclast Precursor Cells by the Sequential Expression of C-Fms and Receptor Activator of Nuclear Factor κb (Rank) Receptors , 1999, The Journal of experimental medicine.
[125] Josef M. Penninger,et al. Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand , 1999, Nature.
[126] T. Martin,et al. Localization of RANKL (receptor activator of NF kappa B ligand) mRNA and protein in skeletal and extraskeletal tissues. , 1999, Bone.
[127] W. Dougall,et al. RANK is essential for osteoclast and lymph node development. , 1999, Genes & development.
[128] L. Lum,et al. Evidence for a Role of a Tumor Necrosis Factor-α (TNF-α)-converting Enzyme-like Protease in Shedding of TRANCE, a TNF Family Member Involved in Osteoclastogenesis and Dendritic Cell Survival* , 1999, The Journal of Biological Chemistry.
[129] S. Morony,et al. TRAF6 deficiency results in osteopetrosis and defective interleukin-1, CD40, and LPS signaling. , 1999, Genes & development.
[130] M. Ueda,et al. Cloning and characterization of the gene encoding mouse osteoclast differentiation factor. , 1999, Gene.
[131] J. Penninger,et al. Osteoprotegerin ligand: A common link between osteoclastogenesis, lymph node formation and lymphocyte development , 1999, Immunology and cell biology.
[132] S. Morony,et al. Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand. , 1999, Proceedings of the National Academy of Sciences of the United States of America.
[133] B. Aggarwal,et al. Activation of NF-kappaB by RANK requires tumor necrosis factor receptor-associated factor (TRAF) 6 and NF-kappaB-inducing kinase. Identification of a novel TRAF6 interaction motif. , 1999, The Journal of biological chemistry.
[134] B. Kwon,et al. Receptor activator of NF‐κB recruits multiple TRAF family adaptors and activates c‐Jun N‐terminal kinase , 1999, FEBS letters.
[135] S. Morony,et al. OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis , 1999, Nature.
[136] W. Dougall,et al. The Involvement of Multiple Tumor Necrosis Factor Receptor (TNFR)-associated Factors in the Signaling Mechanisms of Receptor Activator of NF-κB, a Member of the TNFR Superfamily* , 1998, The Journal of Biological Chemistry.
[137] H. Yasuda,et al. RANK is the essential signaling receptor for osteoclast differentiation factor in osteoclastogenesis. , 1998, Biochemical and biophysical research communications.
[138] R. Steinman,et al. The TRAF Family of Signal Transducers Mediates NF-κB Activation by the TRANCE Receptor* , 1998, The Journal of Biological Chemistry.
[139] T. Martin,et al. A combination of osteoclast differentiation factor and macrophage-colony stimulating factor is sufficient for both human and mouse osteoclast formation in vitro. , 1998, Endocrinology.
[140] John C. Lee,et al. Osteoprotegerin Is a Receptor for the Cytotoxic Ligand TRAIL* , 1998, The Journal of Biological Chemistry.
[141] N. Udagawa,et al. Osteoclast differentiation factor (ODF) induces osteoclast-like cell formation in human peripheral blood mononuclear cell cultures. , 1998, Biochemical and biophysical research communications.
[142] D. Lacey,et al. Osteoprotegerin Ligand Is a Cytokine that Regulates Osteoclast Differentiation and Activation , 1998, Cell.
[143] K Yano,et al. Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[144] R. Steinman,et al. TRANCE (Tumor Necrosis Factor [TNF]-related Activation-induced Cytokine), a New TNF Family Member Predominantly Expressed in T cells, Is a Dendritic Cell–specific Survival Factor , 1997, The Journal of experimental medicine.
[145] R. Dubose,et al. A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function , 1997, Nature.
[146] G Shimamoto,et al. Osteoprotegerin: A Novel Secreted Protein Involved in the Regulation of Bone Density , 1997, Cell.
[147] S Paget,et al. THE DISTRIBUTION OF SECONDARY GROWTHS IN CANCER OF THE BREAST. , 1889 .
[148] F. Saad,et al. Effect of denosumab versus zoledronic acid in preventing skeletal-related events in patients with bone metastases by baseline characteristics. , 2016, European journal of cancer.
[149] U. Weidle,et al. Molecular Mechanisms of Bone Metastasis. , 2016, Cancer genomics & proteomics.
[150] Yongchun Zhu,et al. GPR48 promotes multiple cancer cell proliferation via activation of Wnt signaling. , 2013, Asian Pacific journal of cancer prevention : APJCP.
[151] M. Mason,et al. Expression profile of receptor activator of nuclear-κB (RANK), RANK ligand (RANKL) and osteoprotegerin (OPG) in breast cancer. , 2013, Anticancer research.
[152] Hao Wu,et al. Structural basis of signal transduction in the TNF receptor superfamily. , 2013, Advances in immunology.
[153] K. Akakura. [Inflammatory cytokines]. , 2011, Nihon rinsho. Japanese journal of clinical medicine.
[154] W. Dougall,et al. RANKL acts directly on RANK‐expressing prostate tumor cells and mediates migration and expression of tumor metastasis genes , 2008, The Prostate.
[155] S. Kitano,et al. Receptor activator of nuclear factor-kappaB ligand (RANKL) expression in hepatocellular carcinoma with bone metastasis. , 2007, Annals of surgical oncology.
[156] M. Hansen,et al. Expression of receptor activator of nuclear factor-kappaB is inversely correlated with metastatic phenotype in breast carcinoma. , 2005, Clinical cancer research : an official journal of the American Association for Cancer Research.
[157] G. Dranoff,et al. Cytokines in cancer pathogenesis and cancer therapy , 2004, Nature Reviews Cancer.
[158] Y. Kong,et al. Vascular endothelial growth factor up-regulates expression of receptor activator of NF-kappa B (RANK) in endothelial cells. Concomitant increase of angiogenic responses to RANK ligand. , 2003, The Journal of biological chemistry.
[159] L. To,et al. Receptor activator of nuclear factor-kappaB ligand expression by human myeloma cells mediates osteoclast formation in vitro and correlates with bone destruction in vivo. , 2003, Cancer research.
[160] D. Heymann,et al. Receptor activator of nuclear factor kappaB ligand (RANKL)/osteoprotegerin (OPG) ratio is increased in severe osteolysis. , 2003, The American journal of pathology.
[161] K. Hirokawa,et al. Determination of three isoforms of the receptor activator of nuclear factor-kappaB ligand and their differential expression in bone and thymus. , 2001, Endocrinology.
[162] E. Gallico,et al. [Tumor metastasis]. , 1955, Tumori.